ID   SIN3A_HUMAN             Reviewed;        1273 AA.
AC   Q96ST3; B2RNS5; Q8N8N4; Q8NC83; Q8WV18; Q96L98; Q9UFQ1;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   24-OCT-2003, sequence version 2.
DT   28-JUN-2023, entry version 204.
DE   RecName: Full=Paired amphipathic helix protein Sin3a;
DE   AltName: Full=Histone deacetylase complex subunit Sin3a;
DE   AltName: Full=Transcriptional corepressor Sin3a;
GN   Name=SIN3A {ECO:0000312|HGNC:HGNC:19353};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAP97288.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Guo J.H., Yu L.;
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAH18973.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Uterus {ECO:0000312|EMBL:AAH18973.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1026.
RC   TISSUE=Brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAP97288.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-620.
RA   Bu X., Fu Y., Jiang S., Avraham S., Avraham H.;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 913-1273.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6] {ECO:0000305}
RP   INTERACTION WITH SFPQ.
RX   PubMed=11259580; DOI=10.1128/mcb.21.7.2298-2311.2001;
RA   Mathur M., Tucker P.W., Samuels H.H.;
RT   "PSF is a novel corepressor that mediates its effect through Sin3A and the
RT   DNA binding domain of nuclear hormone receptors.";
RL   Mol. Cell. Biol. 21:2298-2311(2001).
RN   [7]
RP   INTERACTION WITH OGT, AND FUNCTION.
RX   PubMed=12150998; DOI=10.1016/s0092-8674(02)00810-3;
RA   Yang X., Zhang F., Kudlow J.E.;
RT   "Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A:
RT   coupling protein O-GlcNAcylation to transcriptional repression.";
RL   Cell 110:69-80(2002).
RN   [8] {ECO:0000305}
RP   INTERACTION WITH SFPQ.
RX   PubMed=11897684; DOI=10.1210/endo.143.4.8748;
RA   Sewer M.B., Nguyen V.Q., Huang C.J., Tucker P.W., Kagawa N., Waterman M.R.;
RT   "Transcriptional activation of human CYP17 in H295R adrenocortical cells
RT   depends on complex formation among p54(nrb)/NonO, protein-associated
RT   splicing factor, and SF-1, a complex that also participates in repression
RT   of transcription.";
RL   Endocrinology 143:1280-1290(2002).
RN   [9] {ECO:0000305}
RP   INTERACTION WITH DACH1.
RX   PubMed=14525983; DOI=10.1074/jbc.m310021200;
RA   Wu K., Yang Y., Wang C., Davoli M.A., D'Amico M., Li A., Cveklova K.,
RA   Kozmik Z., Lisanti M.P., Russell R.G., Cvekl A., Pestell R.G.;
RT   "DACH1 inhibits transforming growth factor-beta signaling through binding
RT   Smad4.";
RL   J. Biol. Chem. 278:51673-51684(2003).
RN   [10] {ECO:0000305}
RP   INTERACTION WITH HCFC1.
RX   PubMed=12670868; DOI=10.1101/gad.252103;
RA   Wysocka J., Myers M.P., Laherty C.D., Eisenman R.N., Herr W.;
RT   "Human Sin3 deacetylase and trithorax-related Set1/Ash2 histone H3-K4
RT   methyltransferase are tethered together selectively by the cell-
RT   proliferation factor HCF-1.";
RL   Genes Dev. 17:896-911(2003).
RN   [11]
RP   INTERACTION WITH SAP130; SUDS3; ARID4B; HDAC1 AND HDAC2.
RX   PubMed=12724404; DOI=10.1128/mcb.23.10.3456-3467.2003;
RA   Fleischer T.C., Yun U.J., Ayer D.E.;
RT   "Identification and characterization of three new components of the mSin3A
RT   corepressor complex.";
RL   Mol. Cell. Biol. 23:3456-3467(2003).
RN   [12]
RP   INTERACTION WITH BRMS1L.
RX   PubMed=15451426; DOI=10.1016/j.bbrc.2004.08.227;
RA   Nikolaev A.Y., Papanikolaou N.A., Li M., Qin J., Gu W.;
RT   "Identification of a novel BRMS1-homologue protein p40 as a component of
RT   the mSin3A/p33(ING1b)/HDAC1 deacetylase complex.";
RL   Biochem. Biophys. Res. Commun. 323:1216-1222(2004).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-860, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SAP30L.
RX   PubMed=16820529; DOI=10.1093/nar/gkl401;
RA   Viiri K.M., Korkeamaeki H., Kukkonen M.K., Nieminen L.K., Lindfors K.,
RA   Peterson P., Maeki M., Kainulainen H., Lohi O.;
RT   "SAP30L interacts with members of the Sin3A corepressor complex and targets
RT   Sin3A to the nucleolus.";
RL   Nucleic Acids Res. 34:3288-3298(2006).
RN   [15]
RP   INTERACTION WITH PPHLN1.
RX   PubMed=17963697; DOI=10.1016/j.bbrc.2007.10.090;
RA   Kurita M., Suzuki H., Kawano Y., Aiso S., Matsuoka M.;
RT   "CR/periphilin is a transcriptional co-repressor involved in cell cycle
RT   progression.";
RL   Biochem. Biophys. Res. Commun. 364:930-936(2007).
RN   [16]
RP   INTERACTION WITH TOPORS, SUMOYLATION BY TOPORS, AND DESUMOYLATION BY SENP2.
RX   PubMed=17803295; DOI=10.1021/pr0703674;
RA   Pungaliya P., Kulkarni D., Park H.J., Marshall H., Zheng H., Lackland H.,
RA   Saleem A., Rubin E.H.;
RT   "TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins.";
RL   J. Proteome Res. 6:3918-3923(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-277; SER-832; SER-940
RP   AND SER-1112, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-832 AND SER-1112, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-469, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [21]
RP   INTERACTION WITH SPHK2.
RX   PubMed=19729656; DOI=10.1126/science.1176709;
RA   Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K.,
RA   Luo C., Marmorstein R., Kordula T., Milstien S., Spiegel S.;
RT   "Regulation of histone acetylation in the nucleus by sphingosine-1-
RT   phosphate.";
RL   Science 325:1254-1257(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-832; SER-860; SER-940 AND
RP   SER-1112, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INTERACTION WITH TET1.
RX   PubMed=21490601; DOI=10.1038/nature10066;
RA   Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A.,
RA   Rappsilber J., Helin K.;
RT   "TET1 and hydroxymethylcytosine in transcription and DNA methylation
RT   fidelity.";
RL   Nature 473:343-348(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-832 AND SER-860, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10; SER-832; SER-940 AND
RP   SER-1112, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1089, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN WITKOS, AND VARIANT WITKOS
RP   1104-ARG--PRO-1273 DEL.
RX   PubMed=27399968; DOI=10.1038/ng.3619;
RA   Witteveen J.S., Willemsen M.H., Dombroski T.C., van Bakel N.H.,
RA   Nillesen W.M., van Hulten J.A., Jansen E.J., Verkaik D.,
RA   Veenstra-Knol H.E., van Ravenswaaij-Arts C.M., Wassink-Ruiter J.S.,
RA   Vincent M., David A., Le Caignec C., Schieving J., Gilissen C., Foulds N.,
RA   Rump P., Strom T., Cremer K., Zink A.M., Engels H., de Munnik S.A.,
RA   Visser J.E., Brunner H.G., Martens G.J., Pfundt R., Kleefstra T.,
RA   Kolk S.M.;
RT   "Haploinsufficiency of MeCP2-interacting transcriptional co-repressor SIN3A
RT   causes mild intellectual disability by affecting the development of
RT   cortical integrity.";
RL   Nat. Genet. 48:877-887(2016).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-122; LYS-134 AND LYS-563, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [30]
RP   INVOLVEMENT IN WITKOS.
RX   PubMed=30267900; DOI=10.1016/j.ejmg.2018.09.014;
RA   Narumi-Kishimoto Y., Araki N., Migita O., Kawai T., Okamura K.,
RA   Nakabayashi K., Kaname T., Ozawa Y., Ozawa H., Takada F., Hata K.;
RT   "Novel SIN3A mutation identified in a Japanese patient with Witteveen-Kolk
RT   syndrome.";
RL   Eur. J. Med. Genet. 62:103547-103547(2019).
CC   -!- FUNCTION: Acts as a transcriptional repressor. Corepressor for REST.
CC       Interacts with MXI1 to repress MYC responsive genes and antagonize MYC
CC       oncogenic activities. Also interacts with MXD1-MAX heterodimers to
CC       repress transcription by tethering SIN3A to DNA. Acts cooperatively
CC       with OGT to repress transcription in parallel with histone
CC       deacetylation. Involved in the control of the circadian rhythms.
CC       Required for the transcriptional repression of circadian target genes,
CC       such as PER1, mediated by the large PER complex through histone
CC       deacetylation. Cooperates with FOXK1 to regulate cell cycle progression
CC       probably by repressing cell cycle inhibitor genes expression (By
CC       similarity). Required for cortical neuron differentiation and callosal
CC       axon elongation (By similarity). {ECO:0000250|UniProtKB:Q60520,
CC       ECO:0000269|PubMed:12150998}.
CC   -!- SUBUNIT: Interacts with ARID4B, BRMS1L, HCFC1, HDAC1, HDAC2, MXI1,
CC       SAP30L, SAP130, SFPQ and TOPORS (PubMed:11259580, PubMed:11897684,
CC       PubMed:12670868, PubMed:12724404, PubMed:15451426, PubMed:16820529,
CC       PubMed:17803295). Interacts with OGT (via TPRs 1-6); the interaction
CC       mediates transcriptional repression in parallel with histone
CC       deacetylase (PubMed:12150998). Interacts with BAZ2A, MXD1, MXD3, MXD4,
CC       MBD2, DACH1, NCOR1, NR4A2, REST, RLIM, SAP30, SETDB1, SMYD2, and SUDS3
CC       (PubMed:14525983). Interacts with PHF12 in a complex composed of HDAC1,
CC       PHF12 and SAP30 (By similarity). Interacts with TET1; the interaction
CC       recruits SIN3A to gene promoters (PubMed:21490601). The large PER
CC       complex involved in the histone deacetylation is composed of at least
CC       HDAC1, PER2, SFPQ and SIN3A (By similarity). Interacts with KLF11 (By
CC       similarity). Interacts with PPHLN1 (PubMed:17963697). Found in a
CC       complex with YY1, GON4L and HDAC1 (By similarity). Interacts (via PAH2)
CC       with FOXK1 (By similarity). Interacts with FOXK2 (By similarity). Found
CC       in a complex composed of at least SINHCAF, SIN3A, HDAC1, SAP30, RBBP4,
CC       OGT and TET1. Interacts with SINHCAF (By similarity). Interacts with
CC       SPHK2 (PubMed:19729656). {ECO:0000250|UniProtKB:Q60520,
CC       ECO:0000269|PubMed:11259580, ECO:0000269|PubMed:11897684,
CC       ECO:0000269|PubMed:12150998, ECO:0000269|PubMed:12670868,
CC       ECO:0000269|PubMed:12724404, ECO:0000269|PubMed:14525983,
CC       ECO:0000269|PubMed:15451426, ECO:0000269|PubMed:16820529,
CC       ECO:0000269|PubMed:17803295, ECO:0000269|PubMed:17963697,
CC       ECO:0000269|PubMed:19729656, ECO:0000269|PubMed:21490601}.
CC   -!- INTERACTION:
CC       Q96ST3; P51610: HCFC1; NbExp=6; IntAct=EBI-347218, EBI-396176;
CC       Q96ST3; Q13547: HDAC1; NbExp=9; IntAct=EBI-347218, EBI-301834;
CC       Q96ST3; Q92769: HDAC2; NbExp=6; IntAct=EBI-347218, EBI-301821;
CC       Q96ST3; P42858: HTT; NbExp=4; IntAct=EBI-347218, EBI-466029;
CC       Q96ST3; Q9H160: ING2; NbExp=2; IntAct=EBI-347218, EBI-389787;
CC       Q96ST3; P51608: MECP2; NbExp=2; IntAct=EBI-347218, EBI-1189067;
CC       Q96ST3; Q9UQ80: PA2G4; NbExp=4; IntAct=EBI-347218, EBI-924893;
CC       Q96ST3; Q9BUL5: PHF23; NbExp=2; IntAct=EBI-347218, EBI-722852;
CC       Q96ST3; P23246: SFPQ; NbExp=2; IntAct=EBI-347218, EBI-355453;
CC       Q96ST3; P12755: SKI; NbExp=3; IntAct=EBI-347218, EBI-347281;
CC       Q96ST3; P04637: TP53; NbExp=2; IntAct=EBI-347218, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00810,
CC       ECO:0000269|PubMed:16820529}. Nucleus, nucleolus
CC       {ECO:0000269|PubMed:16820529}. Note=Recruited to the nucleolus by
CC       SAP30L.
CC   -!- TISSUE SPECIFICITY: Expressed in the developing brain, with highest
CC       levels of expression detected in the ventricular zone of various
CC       cortical regions. {ECO:0000269|PubMed:27399968}.
CC   -!- PTM: SUMO1 sumoylated by TOPORS. Probably desumoylated by SENP2.
CC       {ECO:0000269|PubMed:17803295}.
CC   -!- DISEASE: Witteveen-Kolk syndrome (WITKOS) [MIM:613406]: An autosomal
CC       dominant syndrome characterized by global developmental delay, mild to
CC       severe intellectual disability, and facial dysmorphism. Additional
CC       features include short stature, microcephaly, joint hypermotility, and
CC       small hands and feet with digital abnormalities. Brain imaging shows
CC       dilated ventricles, thin corpus callosum and, in some cases, dysgyria
CC       or polymicrogyria. {ECO:0000269|PubMed:27399968,
CC       ECO:0000269|PubMed:30267900}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF418569; AAP97288.1; -; mRNA.
DR   EMBL; BC018973; AAH18973.1; -; mRNA.
DR   EMBL; BC137098; AAI37099.1; -; mRNA.
DR   EMBL; BC137099; AAI37100.1; -; mRNA.
DR   EMBL; AK027559; BAB55197.1; -; mRNA.
DR   EMBL; AK074903; BAC11280.1; -; mRNA.
DR   EMBL; AK096477; BAC04801.1; -; mRNA.
DR   EMBL; AY044430; AAK95854.1; -; mRNA.
DR   EMBL; AL117513; CAB55972.1; -; mRNA.
DR   CCDS; CCDS10279.1; -.
DR   PIR; T17282; T17282.
DR   RefSeq; NP_001138829.1; NM_001145357.1.
DR   RefSeq; NP_001138830.1; NM_001145358.1.
DR   RefSeq; NP_056292.1; NM_015477.2.
DR   RefSeq; XP_006720528.1; XM_006720465.3.
DR   RefSeq; XP_006720529.1; XM_006720466.3.
DR   RefSeq; XP_006720530.1; XM_006720467.3.
DR   AlphaFoldDB; Q96ST3; -.
DR   SMR; Q96ST3; -.
DR   BioGRID; 117439; 339.
DR   ComplexPortal; CPX-3321; SIN3A histone deacetylase complex.
DR   ComplexPortal; CPX-3323; SIN3A histone deacetylase complex, ES cell-specific variant.
DR   CORUM; Q96ST3; -.
DR   DIP; DIP-31515N; -.
DR   IntAct; Q96ST3; 109.
DR   MINT; Q96ST3; -.
DR   STRING; 9606.ENSP00000378402; -.
DR   GlyCosmos; Q96ST3; 8 sites, 2 glycans.
DR   GlyGen; Q96ST3; 10 sites, 2 O-linked glycans (10 sites).
DR   iPTMnet; Q96ST3; -.
DR   MetOSite; Q96ST3; -.
DR   PhosphoSitePlus; Q96ST3; -.
DR   SwissPalm; Q96ST3; -.
DR   BioMuta; SIN3A; -.
DR   DMDM; 37999759; -.
DR   EPD; Q96ST3; -.
DR   jPOST; Q96ST3; -.
DR   MassIVE; Q96ST3; -.
DR   MaxQB; Q96ST3; -.
DR   PaxDb; Q96ST3; -.
DR   PeptideAtlas; Q96ST3; -.
DR   ProteomicsDB; 78146; -.
DR   Antibodypedia; 3857; 297 antibodies from 37 providers.
DR   DNASU; 25942; -.
DR   Ensembl; ENST00000360439.8; ENSP00000353622.4; ENSG00000169375.17.
DR   Ensembl; ENST00000394947.8; ENSP00000378402.3; ENSG00000169375.17.
DR   Ensembl; ENST00000394949.8; ENSP00000378403.4; ENSG00000169375.17.
DR   Ensembl; ENST00000564778.6; ENSP00000455204.2; ENSG00000169375.17.
DR   Ensembl; ENST00000565264.2; ENSP00000454296.2; ENSG00000169375.17.
DR   Ensembl; ENST00000704312.1; ENSP00000515834.1; ENSG00000169375.17.
DR   GeneID; 25942; -.
DR   KEGG; hsa:25942; -.
DR   MANE-Select; ENST00000394947.8; ENSP00000378402.3; NM_001145358.2; NP_001138830.1.
DR   UCSC; uc002bai.4; human.
DR   AGR; HGNC:19353; -.
DR   CTD; 25942; -.
DR   DisGeNET; 25942; -.
DR   GeneCards; SIN3A; -.
DR   HGNC; HGNC:19353; SIN3A.
DR   HPA; ENSG00000169375; Low tissue specificity.
DR   MalaCards; SIN3A; -.
DR   MIM; 607776; gene.
DR   MIM; 613406; phenotype.
DR   neXtProt; NX_Q96ST3; -.
DR   OpenTargets; ENSG00000169375; -.
DR   Orphanet; 94065; 15q24 microdeletion syndrome.
DR   Orphanet; 500166; SIN3A-related intellectual disability syndrome due to a point mutation.
DR   PharmGKB; PA134993567; -.
DR   VEuPathDB; HostDB:ENSG00000169375; -.
DR   eggNOG; KOG4204; Eukaryota.
DR   GeneTree; ENSGT00940000155491; -.
DR   HOGENOM; CLU_001360_0_1_1; -.
DR   InParanoid; Q96ST3; -.
DR   OMA; MCEEVIK; -.
DR   OrthoDB; 199155at2759; -.
DR   PhylomeDB; Q96ST3; -.
DR   TreeFam; TF106187; -.
DR   PathwayCommons; Q96ST3; -.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by PPARalpha.
DR   Reactome; R-HSA-427413; NoRC negatively regulates rRNA expression.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   Reactome; R-HSA-9022538; Loss of MECP2 binding ability to 5mC-DNA.
DR   Reactome; R-HSA-9022692; Regulation of MECP2 expression and activity.
DR   Reactome; R-HSA-9022699; MECP2 regulates neuronal receptors and channels.
DR   Reactome; R-HSA-9022702; MECP2 regulates transcription of neuronal ligands.
DR   Reactome; R-HSA-9615017; FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes.
DR   Reactome; R-HSA-9701898; STAT3 nuclear events downstream of ALK signaling.
DR   Reactome; R-HSA-9707564; Cytoprotection by HMOX1.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q96ST3; -.
DR   SIGNOR; Q96ST3; -.
DR   BioGRID-ORCS; 25942; 709 hits in 1173 CRISPR screens.
DR   ChiTaRS; SIN3A; human.
DR   GeneWiki; SIN3A; -.
DR   GenomeRNAi; 25942; -.
DR   Pharos; Q96ST3; Tbio.
DR   PRO; PR:Q96ST3; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q96ST3; protein.
DR   Bgee; ENSG00000169375; Expressed in secondary oocyte and 173 other tissues.
DR   ExpressionAtlas; Q96ST3; baseline and differential.
DR   Genevisible; Q96ST3; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0000118; C:histone deacetylase complex; IDA:UniProtKB.
DR   GO; GO:0000776; C:kinetochore; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0016580; C:Sin3 complex; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcription repressor complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IMP:ARUK-UCL.
DR   GO; GO:0003714; F:transcription corepressor activity; IMP:ARUK-UCL.
DR   GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0002218; P:activation of innate immune response; IMP:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:1903351; P:cellular response to dopamine; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0021895; P:cerebral cortex neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; IEA:Ensembl.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; NAS:ComplexPortal.
DR   GO; GO:0042754; P:negative regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:1900181; P:negative regulation of protein localization to nucleus; IMP:BHF-UCL.
DR   GO; GO:1902455; P:negative regulation of stem cell population maintenance; NAS:ComplexPortal.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:2000678; P:negative regulation of transcription regulatory region DNA binding; IMP:BHF-UCL.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; NAS:ComplexPortal.
DR   GO; GO:0002230; P:positive regulation of defense response to virus by host; IMP:BHF-UCL.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0031453; P:positive regulation of heterochromatin formation; IMP:BHF-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:1902459; P:positive regulation of stem cell population maintenance; NAS:ComplexPortal.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0008104; P:protein localization; IEA:Ensembl.
DR   GO; GO:0030516; P:regulation of axon extension; ISS:UniProtKB.
DR   GO; GO:0010817; P:regulation of hormone levels; IEA:Ensembl.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0051595; P:response to methylglyoxal; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.1160.11; Paired amphipathic helix; 3.
DR   InterPro; IPR013194; HDAC_interact_dom.
DR   InterPro; IPR003822; PAH.
DR   InterPro; IPR036600; PAH_sf.
DR   InterPro; IPR039774; Sin3-like.
DR   InterPro; IPR031693; Sin3_C.
DR   PANTHER; PTHR12346:SF2; PAIRED AMPHIPATHIC HELIX PROTEIN SIN3A; 1.
DR   PANTHER; PTHR12346; SIN3B-RELATED; 1.
DR   Pfam; PF02671; PAH; 3.
DR   Pfam; PF08295; Sin3_corepress; 1.
DR   Pfam; PF16879; Sin3a_C; 1.
DR   SMART; SM00761; HDAC_interact; 1.
DR   SUPFAM; SSF47762; PAH2 domain; 3.
DR   PROSITE; PS51477; PAH; 3.
PE   1: Evidence at protein level;
KW   Acetylation; Biological rhythms; Coiled coil; Disease variant; Dwarfism;
KW   Intellectual disability; Isopeptide bond; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN           1..1273
FT                   /note="Paired amphipathic helix protein Sin3a"
FT                   /id="PRO_0000121537"
FT   DOMAIN          119..189
FT                   /note="PAH 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00810"
FT   DOMAIN          300..383
FT                   /note="PAH 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00810"
FT   DOMAIN          456..525
FT                   /note="PAH 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00810"
FT   REGION          1..23
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          87..110
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          119..196
FT                   /note="Interaction with HCFC1"
FT                   /evidence="ECO:0000269|PubMed:12670868"
FT   REGION          205..480
FT                   /note="Interaction with REST"
FT                   /evidence="ECO:0000250"
FT   REGION          205..297
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          398..446
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          458..525
FT                   /note="Interaction with SAP30"
FT                   /evidence="ECO:0000250|UniProtKB:Q60520"
FT   REGION          523..850
FT                   /note="Interaction with NCOR1"
FT                   /evidence="ECO:0000250|UniProtKB:Q60520"
FT   REGION          524..659
FT                   /note="Interaction with SUDS3 and SAP130"
FT                   /evidence="ECO:0000269|PubMed:12724404"
FT   REGION          687..829
FT                   /note="Interaction with HDAC1 and ARID4B"
FT                   /evidence="ECO:0000269|PubMed:12724404"
FT   REGION          888..967
FT                   /note="Interaction with OGT"
FT                   /evidence="ECO:0000269|PubMed:12150998"
FT   REGION          1136..1156
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          903..932
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        216..250
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        264..282
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        283..297
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        408..430
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:23186163"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         284
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60520"
FT   MOD_RES         469
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         832
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         860
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692"
FT   MOD_RES         865
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60520"
FT   MOD_RES         875
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60520"
FT   MOD_RES         940
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1089
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1112
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   CROSSLNK        122
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        134
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        563
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VARIANT         1104..1273
FT                   /note="Missing (in WITKOS)"
FT                   /evidence="ECO:0000269|PubMed:27399968"
FT                   /id="VAR_081785"
FT   VARIANT         1156
FT                   /note="M -> L (in dbSNP:rs60213317)"
FT                   /id="VAR_062129"
FT   CONFLICT        163
FT                   /note="G -> R (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        170..177
FT                   /note="QLFKGHPD -> HYSKGPPI (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        182..192
FT                   /note="FNTFLPPGYKI -> IQHLFAPWATKM (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="I -> T (in Ref. 3; BAC04801)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        386
FT                   /note="S -> F (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        536
FT                   /note="E -> D (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        562
FT                   /note="P -> G (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        575..576
FT                   /note="PL -> GV (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        595
FT                   /note="S -> C (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        618..620
FT                   /note="ELD -> DLM (in Ref. 4; AAK95854)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1009
FT                   /note="Q -> R (in Ref. 3; BAC11280)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1247..1248
FT                   /note="TT -> NN (in Ref. 1; AAP97288)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1273 AA;  145175 MW;  E6A329BE0EAD84CD CRC64;
     MKRRLDDQES PVYAAQQRRI PGSTEAFPHQ HRVLAPAPPV YEAVSETMQS ATGIQYSVTP
     SYQVSAMPQS SGSHGPAIAA VHSSHHHPTA VQPHGGQVVQ SHAHPAPPVA PVQGQQQFQR
     LKVEDALSYL DQVKLQFGSQ PQVYNDFLDI MKEFKSQSID TPGVISRVSQ LFKGHPDLIM
     GFNTFLPPGY KIEVQTNDMV NVTTPGQVHQ IPTHGIQPQP QPPPQHPSQP SAQSAPAPAQ
     PAPQPPPAKV SKPSQLQAHT PASQQTPPLP PYASPRSPPV QPHTPVTISL GTAPSLQNNQ
     PVEFNHAINY VNKIKNRFQG QPDIYKAFLE ILHTYQKEQR NAKEAGGNYT PALTEQEVYA
     QVARLFKNQE DLLSEFGQFL PDANSSVLLS KTTAEKVDSV RNDHGGTVKK PQLNNKPQRP
     SQNGCQIRRH PTGTTPPVKK KPKLLNLKDS SMADASKHGG GTESLFFDKV RKALRSAEAY
     ENFLRCLVIF NQEVISRAEL VQLVSPFLGK FPELFNWFKN FLGYKESVHL ETYPKERATE
     GIAMEIDYAS CKRLGSSYRA LPKSYQQPKC TGRTPLCKEV LNDTWVSFPS WSEDSTFVSS
     KKTQYEEHIY RCEDERFELD VVLETNLATI RVLEAIQKKL SRLSAEEQAK FRLDNTLGGT
     SEVIHRKALQ RIYADKAADI IDGLRKNPSI AVPIVLKRLK MKEEEWREAQ RGFNKVWREQ
     NEKYYLKSLD HQGINFKQND TKVLRSKSLL NEIESIYDER QEQATEENAG VPVGPHLSLA
     YEDKQILEDA AALIIHHVKR QTGIQKEDKY KIKQIMHHFI PDLLFAQRGD LSDVEEEEEE
     EMDVDEATGA VKKHNGVGGS PPKSKLLFSN TAAQKLRGMD EVYNLFYVNN NWYIFMRLHQ
     ILCLRLLRIC SQAERQIEEE NREREWEREV LGIKRDKSDS PAIQLRLKEP MDVDVEDYYP
     AFLDMVRSLL DGNIDSSQYE DSLREMFTIH AYIAFTMDKL IQSIVRQLQH IVSDEICVQV
     TDLYLAENNN GATGGQLNTQ NSRSLLESTY QRKAEQLMSD ENCFKLMFIQ SQGQVQLTIE
     LLDTEEENSD DPVEAERWSD YVERYMNSDT TSPELREHLA QKPVFLPRNL RRIRKCQRGR
     EQQEKEGKEG NSKKTMENVD SLDKLECRFK LNSYKMVYVI KSEDYMYRRT ALLRAHQSHE
     RVSKRLHQRF QAWVDKWTKE HVPREMAAET SKWLMGEGLE GLVPCTTTCD TETLHFVSIN
     KYRVKYGTVF KAP
//
